Literature DB >> 32130477

Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis.

Alexander Kretschmer1, Robert Bischoff2, Michael Chaloupka2, Friedrich Jokisch2, Thilo Westhofen2, Philipp Weinhold2, Frank Strittmatter2, Armin Becker2, Alexander Buchner2, Christian G Stief2.   

Abstract

PURPOSE: Introduction of robot-assisted radical prostatectomy (RARP) has revolutionized the therapeutic landscape of organ-confined prostate cancer (PCa). However, comparative analyses focused on health-related quality of life (HRQOL) after RARP and open retropubic prostatectomy (ORP) are sparse.
METHODS: In the current retrospective analysis, inclusion criteria encompassed PSA ≤ 10 ng/ml, ≤ pT2c, ISUP ≤ 3, age ≤ 65 years, and preoperative continence. A propensity score-matched patient cohort [n = 418 (ORP: 209, RARP: 209)] was created and HRQOL was prospectively assessed based on validated questionnaires (EORTC QLQ-C30) preoperatively, 3 months, 12 months, and 24 months postoperatively. Primary endpoint was good general HRQOL based on previously published cut-off values. Erectile function was measured via IIEF-5, urinary continence via ICIQ-SF questionnaire. Multivariable analysis included binary logistic regression models (p < 0.05).
RESULTS: Open retropubic prostatectomy and RARP cohorts were well balanced. General HRQOL was significantly higher for ORP compared to RARP after 3 months (70.1 vs. 61.6, p = 0.001), but not at the remaining follow-up time points. There were no significant differences for the remaining QLQ-C30 functioning and symptom scores. In multivariable analysis stratified for IIEF-5 and ICIQ-SF scores and surgeon experience, RARP could be confirmed as a marginally independent predictor for lower ratios of good general HRQOL after 3 months (OR 0.464, 95% CI 0.215-0.999; p = 0.050) without any differences at the remaining time points.
CONCLUSIONS: The current study addresses various HRQOL outcomes over a postoperative period of up to 2 years in a homogenous propensity score-matched contemporary cohort. Marginally better general HRQOL outcomes could be detected for ORP compared to RARP 3 months postoperatively.

Entities:  

Keywords:  EORTC QLQ-C30; Health-related quality of life; Open radical prostatectomy; Robot-assisted radical prostatectomy

Mesh:

Year:  2020        PMID: 32130477     DOI: 10.1007/s00345-020-03144-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  1 in total

1.  Centralization tendencies of retroperitoneal lymph node dissection for testicular cancer in Germany? A total population-based analysis from 2006 to 2015.

Authors:  Christer Groeben; Rainer Koch; Tim Nestler; Klaus Kraywinkel; Angelika Borkowetz; Stefanie Wenzel; Martin Baunacke; Christian Thomas; Johannes Huber
Journal:  World J Urol       Date:  2019-10-11       Impact factor: 4.226

  1 in total
  3 in total

1.  Combined Open Prostatectomy and Kidney Surgery: Feasibility and 12-Month Outcome.

Authors:  Lukas Rath; Friedrich Jokisch; Gerald Bastian Schulz; Alexander Kretschmer; Alexander Buchner; Christian G Stief; Philipp Weinhold
Journal:  Res Rep Urol       Date:  2021-11-23

2.  Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis.

Authors:  Yifeng Mao; Mingqiu Hu; Gaowei Yang; Erke Gao; Wangwang Xu
Journal:  World J Surg Oncol       Date:  2022-08-09       Impact factor: 3.253

3.  Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design.

Authors:  Alexander Kretschmer; Johanna Milow; Chukwuka Eze; Alexander Buchner; Minglun Li; Thilo Westhofen; Frederik Fuchs; Paul Rogowski; Christian Trapp; Ute Ganswindt; Mathias Johannes Zacherl; Leonie Beyer; Vera Wenter; Peter Bartenstein; Boris Schlenker; Christian G Stief; Claus Belka; Nina-Sophie Schmidt-Hegemann
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.